In the recent financial report from Myriad Genetics Inc. (MYGN), here are the key takeaways:
For the third quarter, Myriad Genetics reported a net loss of $22.1 million, significantly improving from a loss of $61.3 million in the same period last year. The earnings per share (EPS) moved from a loss of $0.75 to $0.24 in the same quarter year-over-year. When adjusted for certain items, the company's earnings stood at $0.06 per share for this period, surpassing analysts' expectations, who had projected an EPS of $0.02.
Regarding revenue, Myriad Genetics reported $213.3 million in Q3, up from $191.9 million in the previous year's corresponding quarter.
**Guidance:** For the full fiscal year, the company has provided EPS guidance in the range of $0.12 to $0.14 and expects total revenue to be between $837 million and $843 million.
